	US 11,891,455 B2
	Polymorph form of (r)-2-[2-amino-3-(indol-3-yl)propionylamino]-2- methylpropionic acid and uses thereof
Jozsef Repasi, Erd (HU); Andras Szabo, Budapest (HU); and Markus Henrich, Münzenberg (DE)
Assigned to Galimedix Therapeutics Inc
Appl. No. 17/762,873
Filed by Galimedix Therapeutics Inc., Kensington, MD (US)
PCT Filed Sep. 23, 2020, PCT No. PCT/IB2020/058861 § 371(c)(1), (2) Date Mar. 23, 2022, PCT Pub. No. WO2021/059142, PCT Pub. Date Apr. 1, 2021.
Claims priority of provisional application 62/904,339, filed on Sep. 23, 2019.
Prior Publication US 2022/0389056 A1, Dec. 8, 2022
Int. Cl. C07K 5/078 (2006.01); A61P 27/06 (2006.01)

CPC C07K 5/06156 (2013.01) [A61P 27/06 (2018.01); C07B 2200/13 (2013.01)]

14 Claims

1. Form II of (R)-2-[2-amino-3-(indol-3-yl)propionylamino]-2-methylpropionic acid, characterized by an X-ray powder diffraction pattern displaying peaks at °2θ (d value Å) angles of 5.87 (15.067), 11.91(7.432), 17.99 (4.931), 30.35 (2.945).